I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45.3 SEK 1.59% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InDex Pharmaceuticals Holding AB
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Income from Continuing Operations
-kr269.6m
CAGR 3-Years
-44%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Income from Continuing Operations
-kr480.4m
CAGR 3-Years
8%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Income from Continuing Operations
kr266.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Income from Continuing Operations
kr76.2m
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Income from Continuing Operations
-kr177.8m
CAGR 3-Years
-25%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Income from Continuing Operations
-kr21.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InDex Pharmaceuticals Holding AB
Glance View

Market Cap
3.5B SEK
Industry
Pharmaceuticals

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

FLERIE Intrinsic Value
5.85 SEK
Overvaluation 87%
Intrinsic Value
Price
I

See Also

What is InDex Pharmaceuticals Holding AB's Income from Continuing Operations?
Income from Continuing Operations
-269.6m SEK

Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Income from Continuing Operations amounts to -269.6m SEK.

What is InDex Pharmaceuticals Holding AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-26%

Over the last year, the Income from Continuing Operations growth was -485%. The average annual Income from Continuing Operations growth rates for InDex Pharmaceuticals Holding AB have been -44% over the past three years , -26% over the past five years .

Back to Top